E3 ligase ligand-linker conjugates 36 are primarily utilized in the field of targeted protein degradation, particularly in the development of PROTACs (Proteolysis Targeting Chimeras). These conjugates play a crucial role in bridging the E3 ubiquitin ligase and the target protein of interest, facilitating the ubiquitination and subsequent degradation of the target protein via the proteasome. This approach is especially valuable in drug discovery and therapeutic research, as it allows for the selective elimination of disease-causing proteins, including those traditionally considered "undruggable." By enabling the targeted degradation of proteins involved in cancer, neurodegenerative disorders, and other diseases, E3 ligase ligand-linker conjugates 36 contribute to the advancement of novel treatment strategies with high specificity and efficacy.